WCLC 2026 Highlights: MAVERICK, ADAURA, HARMONi, PAPILLON, DESTINY-Lung04 with Dr. Christine Lovly

World Lung 2026 clinical data establishes new standards for lung cancer management, emphasizing precision and toxicity reduction. Dr. Christine Lovly, a thoracic medical oncologist from City of Hope, highlights the MAVERICK trial’s shift toward MRI surveillance for small cell lung cancer, effectively replacing prophylactic cranial irradiation to preserve cognitive function. The ADORA trial’s eight-year update reinforces adjuvant osimertinib as the standard for early-stage EGFR-mutant non-small cell lung cancer, while the emergence of the PD-1/VEGF bispecific antibody ivonescimab offers a potential new avenue for metastatic disease. Regarding rare mutations, amivantamab plus chemotherapy remains the primary approach for exon 20 insertions, despite the development of novel oral agents. Furthermore, clinical preference for oral HER2-targeted therapies like zongirtinib over TDXd in the first-line setting mitigates risks of severe pneumonitis, underscoring the necessity of biomarker-directed treatment to optimize patient outcomes.